Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment

被引：13
作者：
Gevaert, Thomas [1 ,2 ]
Montironi, Rodolfo [3 ]
Lopez-Beltran, Antonio [4 ,5 ]
Van Leenders, Geert [6 ]
Allory, Yves [7 ]
De Ridder, Dirk [8 ]
Claessens, Frank [9 ]
Kockx, Mark [10 ]
Akand, Murat [11 ]
Joniau, Steven [8 ]
Netto, George [12 ]
Libbrecht, Louis [13 ]
机构：
[1] Katholieke Univ Leuven, Lab Expt Urol, Organ Syst, Leuven, Belgium
[2] AZ Klina, Dept Pathol, Brasschaat, Belgium
[3] Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, Ancona, Italy
[4] Fac Med, Dept Surg & Pathol, Anat Pathol Unit, Cordoba, Spain
[5] Champalimaud Clin Ctr, Lisbon, Portugal
[6] Erasmus Univ, Med Ctr, Dept Pathol, Rotterdam, Netherlands
[7] Univ Paris Est Creteil Val de Marne UPEC, Hop Henri Mondor, Fac Med, Serv Anat Pathol, Creteil, France
[8] Univ Hosp Leuven, Dept Urol, Leuven, Belgium
[9] Katholieke Univ Leuven, Dept Cellular & Mol Med, Mol Endocrinol Lab, Leuven, Belgium
[10] HistoGeneX, Dept Mol Pathol, Antwerp, Belgium
[11] Selcuk Univ, Sch Med, Dept Urol, Konya, Turkey
[12] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[13] Univ Clin St Luc, Dept Pathol, Sint Lambrechts Woluwe, Belgium
来源：
SEMINARS IN CANCER BIOLOGY | 2018年 / 52卷
关键词：
Immunotherapy; Bladder; Kidney; Prostate; Biomarkers; RENAL-CELL CARCINOMA; RESISTANT PROSTATE-CANCER; MISMATCH REPAIR GENES; METASTATIC UROTHELIAL CARCINOMA; INVASIVE BLADDER-CANCER; UPPER URINARY-TRACT; IMMUNE CHECKPOINT INHIBITORS; CISPLATIN-BASED CHEMOTHERAPY; LYNCH SYNDROME; ANDROGEN RECEPTOR;
D O I：
10.1016/j.semcancer.2017.10.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with genito-urinary (GU) cancers at different stages of disease. Robust and reliable biomarkers are crucial for an appropriate inclusion of patients in clinical trials and for a reliable patient selection for treatments with immunomodulatory drugs. The increasing knowledge on the genomic landscape of GU cancers supports stratification of patients for targeted therapies. This review focusses on emerging biomarkers and the role of genomics in predicting clinical benefit to immunomodulatory agents in GU cancers. Based on cancer incidences and available data we restricted this overview to bladder, prostate and renal cancer.
引用
收藏
页码：216 / 227
页数：12
相关论文
共 177 条
  • [21] Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
    Beer, Tomasz M.
    Kwon, Eugene D.
    Drake, Charles G.
    Fizazi, Karim
    Logothetis, Christopher
    Gravis, Gwenaelle
    Ganju, Vinod
    Polikoff, Jonathan
    Saad, Fred
    Humanski, Piotr
    Piulats, Josep M.
    Gonzalez Mella, Pablo
    Ng, Siobhan S.
    Jaeger, Dirk
    Parnis, Francis X.
    Franke, Fabio A.
    Puente, Javier
    Carvajal, Roman
    Sengelov, Lisa
    McHenry, M. Brent
    Varma, Arvind
    van den Eertwegh, Alfonsus J.
    Gerritsen, Winald
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 40 - +
  • [22] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [23] Brannon A Rose, 2010, Genes Cancer, V1, P152
  • [24] ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma
    Brooks, Samira A.
    Brannon, A. Rose
    Parker, Joel S.
    Fisher, Jennifer C.
    Sen, Oishee
    Kattan, Michael W.
    Hakimi, A. Ari
    Hsieh, James J.
    Choueiri, Toni K.
    Tamboli, Pheroze
    Maranchie, Jodi K.
    Hinds, Peter
    Miller, C. Ryan
    Nielsen, Matthew E.
    Rathmell, W. Kimryn
    [J]. EUROPEAN UROLOGY, 2014, 66 (01) : 77 - 84
  • [25] Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
    Brown, Scott D.
    Warren, Rene L.
    Gibb, Ewan A.
    Martin, Spencer D.
    Spinelli, John J.
    Nelson, Brad H.
    Holt, Robert A.
    [J]. GENOME RESEARCH, 2014, 24 (05) : 743 - 750
  • [26] Mutation patterns in genes encoding interferon signaling and antigen presentation: A pan-cancer survey with implications for the use of immune checkpoint inhibitors
    Budczies, Jan
    Bockmayr, Michael
    Klauschen, Frederick
    Endris, Volker
    Froehling, Stefan
    Schirmacher, Peter
    Denkert, Carsten
    Stenzinger, Albrecht
    [J]. GENES CHROMOSOMES & CANCER, 2017, 56 (08) : 651 - 659
  • [27] Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer
    Burger, Maximilian
    Denzinger, Stefan
    Hammerschmied, Christine G.
    Tannapfel, Andrea
    Obermann, Ellen C.
    Wieland, Wolf F.
    Hartmann, Arndt
    Stoehr, Robert
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2006, 84 (10): : 833 - 841
  • [28] Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients
    Cabel, Luc
    Loir, Elika
    Gravis, Gwenaelle
    Lavaud, Pernelle
    Massard, Christophe
    Albiges, Laurence
    Baciarello, Giulia
    Loriot, Yohann
    Fizazi, Karim
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [29] Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
    Callea, Marcella
    Albiges, Laurence
    Gupta, Mamta
    Cheng, Su-Chun
    Genega, Elizabeth M.
    Fay, Andre P.
    Song, Jiaxi
    Carvo, Ingrid
    Bhatt, Rupal S.
    Atkins, Michael B.
    Hodi, F. Stephen
    Choueiri, Toni K.
    McDermott, David F.
    Freeman, Gordon J.
    Signoretti, Sabina
    [J]. CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) : 1158 - 1164
  • [30] Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
    Carthon, Bradley C.
    Wolchok, Jedd D.
    Yuan, Jianda
    Kamat, Ashish
    Tang, Derek S. Ng
    Sun, Jingjing
    Ku, Geoffrey
    Troncoso, Patricia
    Logothetis, Christopher J.
    Allison, James P.
    Sharma, Padmanee
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (10) : 2861 - 2871
12345678910